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In his editorial in the SAMJ of March 2012, Professor Van Niekerk 
clearly describes the differences between traditional and allopathic 
medicine based on their fundamental ways of knowing.1 Traditional 
medicine is centred in the domain of mystica (belief, religion); 
allopathic medicine lies within the domain of empirica (research). He 
acknowledges that modern medicine has evolved from a system of 
beliefs, traditionally adopting and refining natural remedies observed 
to contain successful medicinal properties in the field. Research, in 
particular the use of the randomised controlled trial, should drive 
the process to identify efficacy, non-efficacy and potential harm 
of all potential medicinal products including so-called traditional 
remedies.2
The World Health Organization indicates that up to 80% of 
African populations use traditional medicine, and similar figures 
have been reported in South Africa (SA).3 Therefore, sufficient 
attention is required for a better understanding of the safety, efficacy 
and practice of African traditional medicine in clinical trials. To 
date, there has been limited scientific documentation on the use 
of traditional medicine, especially randomised clinical trials, but 
literature reporting on prevalence, and case studies and case reports, 
have been noted.4,5
Synthesis of results from randomised trials in the form of systematic 
review and meta-analysis can provide clinicians and policymakers 
with the evidence necessary for clinical and regulatory healthcare 
decision-making.6 We conducted systematic reviews of eight widely 
used African traditional plant medicines, and identified only one 
(Pelargonium sidoides), which has been extensively studied in human 
trials albeit none of these on the African continent.7 We identified 
three published trials of plants conducted in Mali8,9 and Nigeria,10 
a report of two unpublished trials,11 and one unconfirmed trial. 
Encouragingly, two plant products (P. sidoides and Niprisan) have 
been evaluated in Cochrane systematic reviews.7,12 In the HIV/AIDS 
field, the first local safety randomised controlled trial of Lessertia 
frutescens (colloquially known as Sutherlandia) was published in 
2007.13 Despite being widely used as an immune booster, there is little 
scientific evidence either for or against its benefit; a phase 2b clinical 
trial is in preparation (personal communication).
Within SA, and across the continent, there is an active and 
growing community of scientists and traditional healers that 
recognises the need for rigorous science to underpin any claims 
made in favour of traditional medicines. The Multi-disciplinary 
University Traditional Health Initiative (MUTHI) is a European 
Union-funded project that aims to build sustainable research 
capacity on plants for better public health in Africa. Running for 
four years, MUTHI comprises a consortium of universities with 
four institutions based in Africa (University of Bamako in Mali, 
University of Makerere in Uganda, and the Universities of the 
Free State and Western Cape (UWC) in South Africa) and three 
based in Europe (Universiteit van Amsterdam in The Netherlands, 
Universitetet I Bergen in Norway, and the University of Oxford 
in the UK). The project comprises five work packages, each with 
a focus on a different aspect of the research process required for 
herbal medicine development. Work packages include ethno-
botany, laboratory techniques, intellectual property rights and 
training in clinical trials. The South African Herbal Science and 
Medicine Institute, UWC, is the lead institution tasked with 
training African investigators in clinical trials methodology.
Prior to implementing MUTHI training in 2011, we conducted a 
training needs assessment of clinical and public health researchers in 
African universities who were planning to conduct clinical research 
on herbal medicines.14 Fifty-seven respondents from 35 institutions 
in 14 African countries identified resource constraints, lack of 
herbal medicine supplies, lack of trained staff, and logistical issues 
as the main obstacles in conducting trials of herbal medicines. They 
requested further training in ethics, statistical analysis, protocol 
design, monitoring and reporting, and publishing of trial results. 
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These capacity deficiencies mirror those identified in a 2008 
SA-focused needs assessment of key stakeholders in the allopathic 
clinical trial landscape.15 The picture is no different globally. In 
a 2011 report published under the auspices of the Organization 
of Economic Co-operation and Development (OECD) Global 
Science Forum, stakeholders and experts from all over the world 
interviewed in a survey reported limited availability of accredited 
trial methodological training for members of the trial team, 
regardless of resource setting.16
To address the gap in trials capacity, MUTHI launched the 
inaugural Clinical Trials Workshop in Cape Town in November 
2011. The content was guided by the needs identified in our survey, 
and participants were also exposed to Good Clinical Practice 
and Good Manufacturing Practice. Fourteen participants from 5 
African countries (South Africa, Mali, Uganda, Sudan and Nigeria) 
were selected to attend after a competitive application process. 
Participants came from several disciplines including basic science, 
medicine, pharmacy and traditional medicine. Further workshops 
are planned for Mali and Uganda in 2013, and an e-learning course 
is under development. 
The OECD has recommended the development of Global Core 
Competencies as a compendium of required knowledge and skills 
for investigators and other members of the clinical trials team, 
research ethics committees, regulatory bodies and trial sponsors. 
Standardised and mutually and internationally recognised accredited 
qualifications in patient-oriented research will be defined, connected 
to these Global Core Competencies.17 Specific issues related to 
intellectual property rights and benefit-sharing arise in clinical trials 
of herbal medicines, especially where communities are vulnerable to 
exploitation. Such Global Core Competencies, to have a truly global 
reach, will need to take cognisance of the need for training in these 
areas.
It is foreseeable that training in clinical trials methodology can 
provide an opportunity for bringing together those working in 
both traditional medicine and allopathic medicine in a learning 
environment. Our experience at MUTHI so far suggests that 
there is a great willingness to learn about the science of medical 
product development among health professionals interested in 
herbal medicines and those working as traditional healers. We agree 
with Van Niekerk that acceptance and respect of difference will 
smooth the path towards better collaboration with the potential of 
discovering new cures.
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